Neointimal thickening after severe coronary artery injury is limited by short-term administration of a factor Xa inhibitor: Results in a porcine model

Circulation

Volumn 93, Issue 8, 1996, Pages 1542-1548

  Schwartz, Robert S ^a   Holder, Daniel J ^b   Holmes Jr , David R ^b   Veinot, John P ^b   Camrud, Allan R ^b   Jorgenson, Michael A ^b   Johnson Jr , Robert G ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

angioplasty; peptides; restenosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; DRUG VEHICLE; HEPARIN; PLACEBO; RECOMBINANT TICK ANTICOAGULANT PEPTIDE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; CORONARY ARTERY DISEASE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; SWINE;

EID: 0029871211     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.8.1542     Document Type: Article

References (45)

1. Anderson H. Restenosis after coronary angioplasty. Dis Mon. 1993; 39:613-670.
2. Holmes DR Jr, Schwartz RS. Restenosis: the clinical problem. Coron Artery Dis. 1993;4:229-231.
3. Lange RA, Willard JE, Hillis LD. Southwestern internal medicine conference: restenosis: the Achilles' heel of coronary angioplasty. Am J Med Sci. 1993;306:265-275.
4. Herrman JP, Hermans WR, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty: the search for the Holy Grail? (pt II). Drugs. 1993;46:249-262.
5. Nicod P, Scherrer U. Explosive growth of coronary angioplasty: success story of a less than perfect procedure. Circulation. 1993;87: 1749-1751. Editorial comment.
6. Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR Jr. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation. 1990;82:2190-2200.
7. Schwartz R, Holmes D Jr, Topol E. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol. 1992;20:1284-1293.
8. Schwartz RS, Edwards WD, Huber KC, Antoniades LA, Bailey KR, Camrud AR, Jorgenson MA, Holmes DR. Coronary restenosis: prospects for solution and new perspectives from a porcine model. Mayo Clin Proc. 1993;68:54-62.
9. Mellott MJ, Stranieri MT, Sitko GR, Stabilito II, Lynch J Jr, Vlasuk GP. Enhancement of recombinant tissue plasminogen activator induced reperfusion by recombinant tick anticoagulant peptide, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis. Fibrinolysis. 1993;7:195-202.
10. Dunwiddie C, Thornberry NA, Bull HG, Sardana M, Friedman PA, Jacobs JW, Simpson E. Antistasin, a leech-derived inhibitor of factor Xa: kinetic analysis of enzyme inhibition and identification of the reactive site. J Biol Chem. 1989;264:16694-16699.
11. Dunwiddie CT, Smith DE, Nutt EM, Vlasuk GP. Anticoagulant effects of the selective factor Xa inhibitors tick anticoagulant peptide and antistasin in the APTT assay are determined by the relative rate of prothrombinase inhibition. Thromb Res. 1991;64: 787-794.
12. Hauptmann J, Kaiser B, Nowak G, Sturzebecher J, Markwardt F. Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors. Thromb Haemost. 1990;63:220-223.
13. Kelly A, Hanson S, Dunwiddie C, Harker L. Safe lasting interruption of arterial thrombosis by transient intravenous administration of tick anticoagulant peptide (TAP). Circulation. 1992; 86(suppl I):I-411. Abstract.
14. Neeper MP, Waxman L, Smith DE, Schulman CA, Sardana M, Ellis RW, Schaffer LW, Siegl PK, Vlasuk GP. Characterization of recombinant tick anticoagulant peptide: a highly selective inhibitor of blood coagulation factor Xa. J Biol Chem. 1990;265:17746-17752.
15. Schaffer LW, Davidson JT, Vlasuk GP, Siegl PK. Antithrombotic efficacy of recombinant tick anticoagulant peptide: a potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation. 1991;84:1741-1748.
16. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide: comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation. 1992;85:805-815.
17. Vlasuk GP, Ramjit D, Fujita T, Dunwiddie CT, Nutt EM, Smith DE, Shebuski RJ. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost. 1991;65:257-262.
18. Lynch JJ Jr, Sitko GR, Mellott MJ, Nutt EM, Lehman ED, Friedman PA, Dunwiddie CT, Vlasuk GP. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy: a comparison of factor Xa versus thrombin inhibition. Cardiovasc Res. 1994;28: 78-85.
19. Jordan SP, Mao SS, Lewis SD, Shafer JA. Reaction pathway for inhibition of blood coagulation factor Xa by tick anticoagulant peptide. Biochemistry. 1992;31:5374-5380.
20. Jordan SP, Waxman L, Smith DE, Vlasuk GP. Tick anticoagulant peptide: kinetic analysis of the recombinant inhibitor with blood coagulation factor Xa. Biochemistry. 1990;29:11095-11100.
21. Dunwiddie CT, Neeper MP, Nutt EM, Waxman L, Smith DE, Hofmann KJ, Lumma PK, Garsky VM, Vlasuk GP. Site-directed analysis of the functional domains in the factor Xa inhibitor tick anticoagulant peptide: identification of two distinct regions that constitute the enzyme recognition sites. Biochemistry. 1992;31: 12126-12131.
22. Vlasuk GP. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost. 1993;70:212-216.
23. Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science. 1990;248:593-596.
24. Huber KC, Schwartz RS, Edwards WD, Camrud AR, Bailey KR, Jorgenson MA, Holmes DR Jr. Effects of angiotensin converting enzyme inhibition on neointimal proliferation in a porcine coronary injury model. Am Heart J. 1993;125:695-701.
25. Schwartz R, Koval T, Edwards W, Camrud A, Bailey K, Browne K, Vlietstra R, Holmes D Jr. Effect of external beam irradiation on neointimal hyperplasia after experimental coronary artery injury. J Am Coll Cardiol. 1992;19:1106-1113.
26. Schwartz R, Huber K, Murphy J, Edwards W, Camrud A, Vlietstra R, Holmes D Jr. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19:267-274.
27. Mosteller F, Tukey J. Data Analysis and Regression. Reading, Mass: Addison-Wesley; 1977.
28. Miller R. The jackknife: a review. Biometrika. 1974;61:1-15.
29. Sardana M, Sardana V, Rodkey J, Wood T, Ng A, Vlasuk GP, Waxman L. Determination of disulfide bond pairs and stability in recombinant tick anticoagulant peptide. J Biol Chem. 1991;266: 13560-13563.
30. Lehmann KG, Laskey MA, Deutsch E, Barnathan E, Laskey WK. Paradoxical increase in restenosis rate with chronic heparin use: influence of heparin therapy on percutaneous transluminal angioplasty outcome in unstable angina pectoris. J Am Coll Cardiol. 1991;17:181A. Abstract.
31. Jordan S, Waxman L, Smite D, Vlasuk G. Tick anticoagulant peptide: kinetic analysis of the recombinant inhibitor with blood coagulation factor Xa. Biochemistry. 1990;29:11095-11100.
32. 31a. Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ, van Dijk R, van den Bos AA, Umans VA, Fox KA. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty: Helvetica Investigators. N Engl J Med. 1995; 333:757-763.
33. Ellis SG, Roubin GS, Wilentz J, Douglas JS Jr, King SB III. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J. 1989;117: 777-782.
34. Laskey MA, Deutsch E, Barnathan E, Laskey WK. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectoris. Am J Cardiol. 1990;65: 1425-1429.
35. Cardoso PF, Yamazaki F, Keshavjee S, Schaefers HJ, Hsieh CM Wang LS, Glynn MF, Patterson GA, Cooper JD. A reevaluation of heparin requirements for cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1991;101:153-160.
36. Thomason T, Riegel B, Jessen D, Smith SC Jr, Gocka I, Rich M. Clinical safety and cost of heparin titration using bedside activated clotting time. Am J Crit Care. 1993;2:81-87.
37. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuseer R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496-501.
38. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand B, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel M. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-495.
39. Fuster V, Badimon L, Badimon JJ, Ip JH, Chesebro JH. The porcine model for the understanding of thrombogenesis and atherogenesis. Mayo Clin Proc. 1991;66:818-831.
40. Heras M, Chesebro JH, Penny WJ, Bailey KR, Lam JY, Holmes DR, Reeder GS, Badimon L, Fuster V. Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation. 1988;78:654-660.
41. Heras M, Chesebro JH, Webster MW, Mruk JS, Grill DE, Fuster V. Antithrombotic efficacy of low-molecular-weight heparin in deep arterial injury. Arterioscler Thromb. 1992;12:250-255.
42. Gasic GP, Arenas CP, Gasic TB, Gasic GJ. Coagulation factors X, Xa and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci U S A. 1992;89:2317-2320.
43. Escaned J, de Jong M, Violaris AG, MacLeod DC, Umans VA, van Suylen RJ, de Feyter PJ, Verdouw PD, Serruys PW. Clinical and histological determinants of smooth-muscle cell outgrowth in cultured atherectomy specimens: importance of thrombus organization. Coron Artery Dis. 1993;4:883-890.
44. Ragosta M, Gimple LW, Gertz SD, Dunwiddie CT, Vlasuk GP, Haber HL, Powers ER, Roberts WC, Sarembock IJ. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation. 1994;89: 1262-1271.
45. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand B, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel M. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-495.